ACCELERON PHARMA INC
ACCELERON PHARMA INC (XLRN): 4 pipeline candidates · ~26 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
25.8 months
D/E 0.10 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for ACCELERON PHARMA INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$337.9M
Quarterly Burn
$70.9M
Runway
25.8 mo
Revenue
$34.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| ace-1334 | Phase 1 |
| reblozyl | Approved |
| sotatercept | Phase 2 |
| sotatercept 0.3 mg/kg escalating to | Phase 2 |
Frequently asked questions
How many drug candidates are in ACCELERON PHARMA INC's pipeline?
ACCELERON PHARMA INC (XLRN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ACCELERON PHARMA INC's lead drug candidate?
ACCELERON PHARMA INC's most advanced tracked candidate is ace-1334 (Phase 1) for systemic sclerosis-associated interstitial lung disease (SSc-ILD).
What is ACCELERON PHARMA INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ACCELERON PHARMA INC has approximately 25.8 months of cash runway.
Who is the CEO of ACCELERON PHARMA INC?
Habib J. Dable is the chief executive officer of ACCELERON PHARMA INC (XLRN).
Get the full picture on ACCELERON PHARMA INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.